+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Hepatitis A immunoglobulin Market by End User (Ambulatory Surgical Centers, Clinics, Diagnostic Centers), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Indication, Product Type, Form - Global Forecast 2025-2030- Product Image
Hepatitis A immunoglobulin Market by End User (Ambulatory Surgical Centers, Clinics, Diagnostic Centers), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Indication, Product Type, Form - Global Forecast 2025-2030- Product Image
New

Hepatitis A immunoglobulin Market by End User (Ambulatory Surgical Centers, Clinics, Diagnostic Centers), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Indication, Product Type, Form - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 192 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6152618
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Comprehensive Overview of the Hepatitis A Immunoglobulin Executive Summary Introduction Highlighting Objectives and Structural Framework

The introduction establishes the foundational context for understanding the hepatitis A immunoglobulin segment, setting forth the objectives, scope, and structural approach of the executive summary. It frames the purpose of the analysis by highlighting the importance of immunoglobulin therapies in postexposure and preexposure prophylaxis, positioning them as essential tools in the prevention and mitigation of hepatitis A outbreaks. This orientation emphasizes the interplay between clinical efficacy, manufacturing processes, and market access considerations that drive strategic planning.

Building on this contextual framework, the report delineates the primary themes to be explored, including regulatory shifts, tariff impacts, segmentation insights, and regional dynamics. It outlines the methodologies employed to synthesize data from diverse sources, ensuring transparency and credibility in the analysis. By clarifying the report’s architecture, stakeholders will navigate the subsequent sections with a clear understanding of how each element contributes to a cohesive narrative. This structured introduction underscores the report’s commitment to delivering actionable intelligence for decision-makers across clinical, manufacturing, and distribution channels.

Emerging Dynamics and Transformative Shifts Reshaping the Hepatitis A Immunoglobulin Landscape Across Clinical, Regulatory, and Technological Frontiers

Over recent years, the hepatitis A immunoglobulin landscape has undergone transformative shifts driven by clinical innovations, regulatory recalibrations, and technological advancements. In clinical practice, guidelines have evolved to recommend more nuanced prophylactic regimens, reflecting improved understanding of immunoglobulin dosing and timing. Concurrently, regulatory bodies have introduced expedited pathways for plasma-derived products, accelerating their availability while enforcing stringent safety protocols.

Technological progress in plasma fractionation and purification has enhanced product consistency and reduced contamination risks, leading to expanded distribution networks and improved cold chain logistics. These advances have enabled manufacturers to optimize yield from human and equine sources, increasing resilience against supply disruptions. In parallel, digital monitoring systems now track inventory and temperature conditions in real time, bolstering delivery reliability.

This convergence of clinical, regulatory, and manufacturing trends has redefined competitive dynamics, compelling stakeholders to reassess strategic priorities. Organizations that invest in robust quality management systems and agile production capacities are better positioned to respond to emergent public health needs. As a result, the immunoglobulin market is experiencing a shift from transactional supply models toward integrated partnerships that emphasize long-term reliability and shared risk management.

Comprehensive Analysis of the 2025 United States Tariff Impact on Hepatitis A Immunoglobulin Supply Chains, Pricing, and Clinical Accessibility

In 2025, the introduction of adjusted tariff schedules in the United States has exerted significant pressure on the cost structures and supply chain continuity for hepatitis A immunoglobulin. Manufacturers importing raw plasma components have encountered elevated duties, prompting strategic reviews of sourcing strategies. As a result, some producers have accelerated vertical integration efforts to mitigate tariff exposure, investing in domestic plasma collection infrastructure to preserve margin stability.

These shifts have also influenced distribution costs, as increased duties translate into higher landed prices across hospital and retail pharmacy channels. Payers and procurement teams are negotiating revised contracts to absorb or pass on these incremental expenses, which has led to renegotiations of reimbursement levels and co-pay structures. In response, manufacturers have explored localized fill-finish operations to reduce cross-border freight and duty liabilities.

Despite these challenges, the industry has leveraged tariff-induced disruption as an impetus for innovation. Collaborative agreements between plasma fractionators and contract manufacturing organizations have materialized to share capacity and optimize cost efficiencies. As a result, supply chains have grown more resilient, incorporating redundant distribution nodes and enhanced inventory buffers. This adaptive response underscores the sector’s ability to navigate the geopolitical complexities that influence market access.

Segmentation Insights Revealing End User Distribution Channel Indication Product Type and Form Trends Shaping the Hepatitis A Immunoglobulin Market Dynamics

A granular examination of market segments reveals nuanced patterns across end user categories, distribution channels, indications, product types, and dosage forms. Ambulatory surgical centers, clinics, diagnostic centers, and hospitals demonstrate distinct procurement behaviors, with hospitals often driving volume through both in-house and contract pharmacy models. Meanwhile, direct-to-consumer and third-party marketplaces have emerged within the online pharmacy space, complementing traditional chain and independent retail outlets.

On the clinical front, differentiation arises between postexposure prophylaxis protocols, which prioritize rapid administration of a single-dose regimen, and preexposure prophylaxis strategies that focus on scheduled dosing for high-risk populations. These therapeutic distinctions directly influence inventory turnover and forecasting methodologies.

From a manufacturing perspective, the coexistence of equine and human plasma-derived products underscores varied safety and supply risk profiles, while liquid formulations facilitate immediate clinical use and lyophilized variants enhance storage stability in resource-constrained environments. Collectively, these segmentation insights illuminate the pathways through which stakeholders can tailor product portfolios and distribution approaches to align with specific end user requirements and patient safety imperatives.

Strategic Regional Insights Highlighting Market Trajectories Across the Americas Europe Middle East Africa and AsiaPacific Geographies

Regional analysis underscores differentiated growth trajectories and market dynamics across major geographies. In the Americas, robust plasma donation frameworks and established reimbursement environments underpin high adoption rates, particularly within hospital pharmacy channels. By contrast, Europe, the Middle East, and Africa exhibit variable regulatory harmonization, prompting manufacturers to navigate a mosaic of approval processes and national procurement policies to secure market entry.

Meanwhile, the Asia-Pacific region has experienced rapid expansion in plasma collection and fractionation capacity, driven by concerted investments in biomanufacturing infrastructure. This has translated into improved access for both liquid and lyophilized immunoglobulin formulations, especially within diagnostic centers and clinics. Collaborative public-private partnerships have further accelerated distribution reach into remote areas, enhancing outbreak response capabilities.

Across these distinct regions, logistical considerations such as cold chain integrity, cross-border tariff regimes, and local fill-finish capabilities inform strategic deployment plans. By leveraging regional strengths and addressing specific barriers, stakeholders can optimize supply networks and align commercial strategies with evolving clinical and regulatory landscapes.

Key Corporate Profiles and Competitive Insights Uncovering Strategic Initiatives Product Portfolios Collaborations and Innovation Pipelines of Leading Industry Participants

Leading companies in the hepatitis A immunoglobulin market have differentiated themselves through targeted investments in plasma sourcing, manufacturing innovation, and strategic collaborations. Several global plasma fractionators have expanded their footprint by establishing dedicated in-house pharmacy operations within major hospital systems, securing preferential procurement agreements. Others have forged alliances with contract manufacturing organizations to enhance fill-finish capacity, reducing time to market for lyophilized and liquid formulations.

In parallel, key industry players have prioritized research and development partnerships with academic institutions to explore next-generation immunoglobulin purification techniques. These collaborations have yielded proprietary monoclonal enrichment processes that improve product purity while reducing manufacturing timelines. Some companies have also integrated digital tracking platforms across their distribution networks, enabling real-time visibility into cold chain conditions and inventory status.

Competitive dynamics are further shaped by selective licensing agreements for equine plasma products in markets with limited human donation resources, offering flexible alternatives for emergency prophylaxis. This multi-pronged strategic approach underscores the emphasis on resilience, quality assurance, and regulatory compliance that defines the current competitive landscape.

Actionable Strategic Recommendations Enabling Industry Leaders to Navigate Supply Chain Challenges Regulatory Complexities and Evolving Clinical Demand for Hepatitis A Immunoglobulin

Industry leaders should proactively diversify plasma sourcing channels to mitigate the impact of fluctuating tariff environments and potential donation shortfalls. Establishing strategic collaborations with regional plasma collection centers can enhance supply security and reduce logistical complexity. Concurrently, investing in fill-finish capabilities near key clinical markets will lower cross-border costs and accelerate response times during outbreak scenarios.

Engaging early with regulatory authorities to clarify expedited approval pathways for both human and equine plasma-derived products will streamline market entry and reinforce compliance. Implementing robust digital supply chain monitoring solutions will provide real-time insights into cold chain integrity, inventory levels, and distribution performance, enabling rapid course corrections.

On the commercial front, tailoring distribution strategies to end user preferences-whether through in-house hospital pharmacies, direct-to-consumer channels, or third-party marketplaces-will drive optimized reach. Investing in clinical education programs for healthcare providers can amplify adoption of prophylactic protocols, while outcome-based contracting models may align stakeholder incentives around patient safety and cost efficiency.

Robust Research Methodology Detailing Primary Secondary Data Collection Analytical Techniques and Triangulation Approaches to Ensure Data Integrity and Accuracy

The research methodology combines rigorous secondary research with targeted primary engagements to deliver comprehensive insights. Initially, an extensive literature review of peer-reviewed journals, regulatory filings, and industry white papers was conducted to map historical trends in immunoglobulin production and clinical usage. This foundation informed the identification of key stakeholders for in-depth interviews.

Primary research included qualitative discussions with senior executives across plasma fractionation firms, manufacturing experts, hospital pharmacy directors, and policy advisors. These interviews provided firsthand perspectives on tariff impacts, regulatory requirements, and supply chain resilience strategies. Data triangulation was achieved by cross-referencing interview findings with supply chain performance metrics and regulatory approval timelines.

Analytical techniques such as trend analysis, scenario planning, and sensitivity testing were employed to assess the robustness of strategic recommendations. Quality assurance protocols ensured data integrity through multiple validation checkpoints and peer reviews, resulting in a reliable framework for stakeholders to leverage in decision-making processes.

Conclusive Synthesis of Hepatitis A Immunoglobulin Market Analysis Highlighting Strategic Implications Key Findings and Future Directions for Stakeholders and PolicyMakers

The synthesis of clinical advancements, tariff dynamics, segmentation insights, regional considerations, and competitive strategies yields a holistic view of the hepatitis A immunoglobulin market. Stakeholders can leverage emerging manufacturing technologies and strategic partnerships to safeguard supply continuity, while structured engagement with regulatory authorities will facilitate timely approvals and market access.

Segmentation analysis illuminates pathways for product differentiation across end users, distribution channels, and patient indications, underscoring the importance of tailored delivery models. Regional insights highlight the need for adaptive strategies that address local regulatory landscapes, logistical constraints, and evolving clinical protocols. Competitive intelligence reveals a landscape characterized by collaborative innovation, digital integration, and strategic licensing arrangements.

In conclusion, the convergence of these factors points to a market that rewards agility, strategic foresight, and operational excellence. Organizations that align their initiatives across sourcing, manufacturing, distribution, and stakeholder engagement will be best positioned to navigate uncertainties and capture growth opportunities.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • End User
    • Ambulatory Surgical Centers
    • Clinics
    • Diagnostic Centers
    • Hospitals
  • Distribution Channel
    • Hospital Pharmacy
      • Contract Pharmacy
      • In-House Pharmacy
    • Online Pharmacy
      • Direct-To-Consumer
      • Third-Party Marketplace
    • Retail Pharmacy
      • Chain Pharmacy
      • Independent Pharmacy
  • Indication
    • Postexposure Prophylaxis
    • Preexposure Prophylaxis
  • Product Type
    • Equine
    • Human Plasma Derived
  • Form
    • Liquid
    • Lyophilized
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Grifols S.A.
  • CSL Limited
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • Biotest AG
  • Kedrion S.p.A.
  • LFB S.A.
  • Bio Products Laboratory Ltd
  • Serum Institute of India Pvt. Ltd.
  • GC Biopharma Co., Ltd.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Expansion of travel medicine clinics boosting demand for hepatitis A immunoglobulin in global tourist hotspots
5.2. Regulatory approval of new high-concentration hepatitis A immunoglobulin formulations improving passive immunity in pediatric patients
5.3. Strategic collaborations between biopharmaceutical companies and contract manufacturing organizations to scale up hepatitis A immunoglobulin production capacity
5.4. Rising incidence of hepatitis A outbreaks in developing regions driving increased government procurement of immunoglobulin
5.5. Integration of hepatitis A immunoglobulin prophylaxis into routine post-exposure protocols in childcare and school settings
5.6. Technological advancements in antibody purification techniques driving cost-effective hepatitis A immunoglobulin yields
5.7. Implementation of cold chain optimization strategies to enhance distribution efficiency of hepatitis A immunoglobulin in remote areas
5.8. Surge in corporate travel and business tourism accelerating prophylactic hepatitis A immunoglobulin uptake among frequent travellers
5.9. Adoption of evidence-based dosing guidelines by healthcare professionals for hepatitis A immunoglobulin use in immunocompromised patients
5.10. Growing investment in recombinant antibody platforms challenging plasma-derived hepatitis A immunoglobulin manufacturers' market share
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Hepatitis A immunoglobulin Market, by End User
8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Clinics
8.4. Diagnostic Centers
8.5. Hospitals
9. Hepatitis A immunoglobulin Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.2.1. Contract Pharmacy
9.2.2. In-House Pharmacy
9.3. Online Pharmacy
9.3.1. Direct-To-Consumer
9.3.2. Third-Party Marketplace
9.4. Retail Pharmacy
9.4.1. Chain Pharmacy
9.4.2. Independent Pharmacy
10. Hepatitis A immunoglobulin Market, by Indication
10.1. Introduction
10.2. Postexposure Prophylaxis
10.3. Preexposure Prophylaxis
11. Hepatitis A immunoglobulin Market, by Product Type
11.1. Introduction
11.2. Equine
11.3. Human Plasma Derived
12. Hepatitis A immunoglobulin Market, by Form
12.1. Introduction
12.2. Liquid
12.3. Lyophilized
13. Americas Hepatitis A immunoglobulin Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Hepatitis A immunoglobulin Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Hepatitis A immunoglobulin Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Grifols S.A.
16.3.2. CSL Limited
16.3.3. Takeda Pharmaceutical Company Limited
16.3.4. Octapharma AG
16.3.5. Biotest AG
16.3.6. Kedrion S.p.A.
16.3.7. LFB S.A.
16.3.8. Bio Products Laboratory Ltd
16.3.9. Serum Institute of India Pvt. Ltd.
16.3.10. GC Biopharma Co., Ltd.
17. Research AI18. Research Statistics19. Research Contacts20. Research Articles21. Appendix
List of Figures
FIGURE 1. HEPATITIS A IMMUNOGLOBULIN MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 6. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. HEPATITIS A IMMUNOGLOBULIN MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. HEPATITIS A IMMUNOGLOBULIN MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. HEPATITIS A IMMUNOGLOBULIN MARKET: RESEARCHAI
FIGURE 26. HEPATITIS A IMMUNOGLOBULIN MARKET: RESEARCHSTATISTICS
FIGURE 27. HEPATITIS A IMMUNOGLOBULIN MARKET: RESEARCHCONTACTS
FIGURE 28. HEPATITIS A IMMUNOGLOBULIN MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. HEPATITIS A IMMUNOGLOBULIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY CONTRACT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY CONTRACT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY IN-HOUSE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY IN-HOUSE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DIRECT-TO-CONSUMER, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DIRECT-TO-CONSUMER, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY THIRD-PARTY MARKETPLACE, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY THIRD-PARTY MARKETPLACE, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY POSTEXPOSURE PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY POSTEXPOSURE PROPHYLAXIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PREEXPOSURE PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PREEXPOSURE PROPHYLAXIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY EQUINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY EQUINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HUMAN PLASMA DERIVED, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HUMAN PLASMA DERIVED, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY LIQUID, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY LYOPHILIZED, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 99. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 104. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 105. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 106. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 107. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 108. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 109. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 110. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 111. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 112. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 113. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 114. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 115. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 116. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 117. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 118. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 119. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 120. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 121. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 122. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 123. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 124. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 125. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 126. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 127. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 128. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 129. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 130. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 197. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 200. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 201. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 202. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 203. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 204. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 205. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 206. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 207. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 208. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 209. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 210. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 211. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 212. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 213. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 214. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 215. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 216. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 217. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 218. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 219. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 220. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 221. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 222. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 223. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 224. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 225. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 226. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 227. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 228. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 229. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 245. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 250. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 251. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 252. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 253. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 254. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 255. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 256. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 257. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 258. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 259. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 260. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 261. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 262. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 263. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 264. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 265. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 266. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 267. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 268. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 269. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 270. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 271. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 272. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 273. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 274. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 275. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 276. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 293. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 294. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 295. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 296. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 298. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 300. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 302. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 304. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 306. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 308. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 309. SOUTH AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 310. SOUTH AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 311. SOUTH AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 312. SOUTH AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 314. SOUTH AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 316. SO

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Hepatitis A immunoglobulin Market report include:
  • Grifols S.A.
  • CSL Limited
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • Biotest AG
  • Kedrion S.p.A.
  • LFB S.A.
  • Bio Products Laboratory Ltd
  • Serum Institute of India Pvt. Ltd.
  • GC Biopharma Co., Ltd.

Related Topics

Related Reports

Human Hepatitis B Immunoglobulin Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Human Hepatitis B Immunoglobulin Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 98 Pages
  • Global
From
Immunoglobulin Product Market by Source (Pooled Human Plasma, Recombinant), Product Type (Hyperimmune Globulin, Standard Immunoglobulin), Route Of Administration, Application - Global Forecast 2025-2030 - Product Image

Immunoglobulin Product Market by Source (Pooled Human Plasma, Recombinant), Product Type (Hyperimmune Globulin, Standard Immunoglobulin), Route Of Administration, Application - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From
Subcutaneous Immunoglobulin - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Subcutaneous Immunoglobulin - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 120 Pages
  • Global
From
Chronic Liver Diseases Therapeutics Global Market Report 2025 - Product Image

Chronic Liver Diseases Therapeutics Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Global Liver Disease Market, Global Forecast 2023-2027, Industry Trends, Growth, Insight, Impact of Inflation, Company Analysis - Product Image

Global Liver Disease Market, Global Forecast 2023-2027, Industry Trends, Growth, Insight, Impact of Inflation, Company Analysis

  • Report
  • 140 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.